Telix Pharmaceuticals Ltd
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $TLX in the last 30 days.
See all $TLX insider activity →Telix Pharmaceuticals reported a $38M profit after tax for H1 2026, including a $40M payment from Regeneron. Revenue rose 22% YoY to $477M, with adjusted EBITDA up 146% to $52M. R&D spending increased to $124M. The company expects 2026 revenue to exceed $1B, including the Regeneron payment.
US equities showed mixed after-hours movement. Quantum computing and rare earth stocks rose, with SELLAS (SLS) up 15.37%, IQM (IQMX) up 14.77%, and USA Rare Earth (USAR) up 12.57%. Robinhood (HOOD) gained 13.70%. Crypto miners fell, with Hut 8 (HUT) down 8.79% and Cipher (CIFR) down 8.40%. Alibaba (BABA) dropped 8.57%, and Seabridge Gold (SA) fell 9.35%.
US equities show sharp divergence midday. Robinhood (HOOD) +13.28%, Moderna (MRNA) +12.01%, Hut 8 (HUT) -9.51%, Alibaba (BABA) -7.01%. Other movers include TG Therapeutics (TGTX), USA Rare Earth (USAR), Infleqtion (INFQ), OSI Systems (OSIS), Telix Pharmaceuticals (TLX), Seabridge Gold (SA).
Over the past 7 days, alphai's AI scored 2 news stories mentioning TLX (Telix Pharmaceuticals Ltd). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent TLX coverage spans earnings, market movers and financial news.
Strong top‑line growth and a non‑recurring $40M payment boost earnings, while cash balance of $252M and new convertible bond issuance improve liquidity.
Biotech stock decline mirrors broader market weakness.
Radiopharma stock declines sharply.
Positive earnings beat and pipeline milestones may boost TLX share price.
Guidance beat expectations, supporting a potential upside in TLX share price.
alphai scores every news story that mentions TLX with an AI model for sentiment and relevance, and aggregates insider trades from Telix Pharmaceuticals Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
Telix Pharmaceuticals reported a $38M profit after tax for H1 2026, including a $40M payment from Regeneron. Revenue rose 22% YoY to $477M, with adjusted EBITDA up 146% to $52M. R&D spending increased to $124M. The company expects 2026 revenue to exceed $1B, including the Regeneron payment.
2 min readUS equities showed mixed after-hours movement. Quantum computing and rare earth stocks rose, with SELLAS (SLS) up 15.37%, IQM (IQMX) up 14.77%, and USA Rare Earth (USAR) up 12.57%. Robinhood (HOOD) gained 13.70%. Crypto miners fell, with Hut 8 (HUT) down 8.79% and Cipher (CIFR) down 8.40%. Alibaba (BABA) dropped 8.57%, and Seabridge Gold (SA) fell 9.35%.
2 min readUS equities show sharp divergence midday. Robinhood (HOOD) +13.28%, Moderna (MRNA) +12.01%, Hut 8 (HUT) -9.51%, Alibaba (BABA) -7.01%. Other movers include TG Therapeutics (TGTX), USA Rare Earth (USAR), Infleqtion (INFQ), OSI Systems (OSIS), Telix Pharmaceuticals (TLX), Seabridge Gold (SA).
2 min readTelix Pharmaceuticals reported H1 earnings, with precision medicine EBITDA up 26% YoY to AUD 132M. Telix Manufacturing Solutions revenue rose 10% YoY to AUD 89M, while internal revenue via RLS increased 70% to AUD 57M. The company's PSMA imaging portfolio revenue grew 9% sequentially to $202M. Telix is investing in manufacturing and distribution capacity and has regulatory updates for Pixclara and Zircaix. The BiPASS study is nearing enrollment completion, potentially doubling the PSMA imaging m
2 min readTelix Pharmaceuticals reaffirmed its FY26 guidance, projecting revenue of $950M-$970M and total income exceeding $1B, including $40M from Regeneron. H1 2026 revenue rose 22% YoY to $477M, with adjusted EBITDA up 146% to $52M. The company's strong performance is partly driven by a one-time payment from Regeneron.
2 min readTelix Pharmaceuticals reported H1 2026 revenue of US$477M, up 22% YoY, with gross margin at 55%. Adjusted EBITDA rose 146% to US$52M. The company expects FY 2026 revenue to exceed US$1B. Key milestones include FDA and EMA reviews for Pixclara and Pixlumi, and progress in clinical trials for prostate and kidney cancer therapies.
2 min readTelix Pharmaceuticals reported H1 2026 revenue of $477M, up 22% YoY, with gross margin at 55%. Adjusted EBITDA rose 146% to $52M, driven by Precision Medicine sales and a $40M Regeneron collaboration payment. Profit after tax was $38M, reversing a $2M loss from H1 2025. The company expects FY 2026 revenue to exceed $1B and has established a Nasdaq at-the-market equity facility.
2 min readTelix Pharmaceuticals Ltd (TLX) furnished an SEC Form 6-K — earnings release. Telix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne, Victoria, 3051 Australia Appendix 4D Half-year ended June 30, 2026 Results announcement to the market Current Reporting Period: June 30, 2026 Previous Reporting Period: June 30, 2025 This page and t
2 min readTelix Pharmaceuticals reported H1 2026 revenue of $477M, up 22% YoY, with EBITDA rising 146% and net profit at $38M. Growth was driven by Precision Medicine, global expansion, and new product launches. The company increased R&D investment and manufacturing capacity.
1 min readASX 200 ended slightly lower on the day, down 0.09% to 9,263.60, but rose 3.2% for the week. Materials gained 1.32% as gold prices neared $4,300/oz. Gold and lithium stocks led, including Genesis Minerals (GMD), Capricorn Metals (CMM), Vault Minerals (VAU) and Liontown (LTR). ResMed (RMD) and 4DMedical (4DX) fell.
4 min read
